Estriol (E3)

Who May Benefit from Estriol Therapy?

Postmenopausal women

Estriol is a weaker, short‑acting estrogen that may support postmenopausal women by helping maintain urogenital tissue health and providing relief from symptoms related to low estrogen levels. Its unique profile and lower receptor potency have led to growing interest in its potential to offer benefits with fewer effects typically associated with stronger estrogens.

Bone health concerns

Estriol’s weaker estrogenic activity has been associated with supporting bone maintenance that may limit bone resorption. Its use has been explored in those with age‑related bone‑health concerns, where maintaining bone density is important for long‑term skeletal strength.

Certain autoimmune or inflammatory conditions

Estriol has emerging immunomodulatory properties that may help regulate immune activity in certain autoimmune or inflammatory conditions. Research suggests it may influence pro‑inflammatory cytokines and support immune balance in disorders such as multiple sclerosis and rheumatoid arthritis.

What are bioidentical hormones?

Bioidentical hormones, predominantly isolated from plant materials, have the exact chemical and molecular structure as hormones made in the human body. Bioidentical steroid hormones like estriol are designed to bind to the same receptors and undergo similar enzymatic breakdown. Dose and delivery route are essential to activity, which is why compounded bioidentical hormone replacement therapy (BHRT) offers distinctive options that maximize therapeutic use.

Access clinical studies on Estriol

• Lephart ED, Naftolin F. Menopause and the Skin: Old Favorites and New Innovations in Cosmeceuticals for Estrogen-Deficient Skin. Dermatol Ther (Heidelb). 2021 Feb;11(1):53-69. doi: 10.1007/s13555-020-00468-7. Epub 2020 Nov 26. PMID: 33242128; PMCID: PMC7859014.
• Samaras N, Papadopoulou MA, Samaras D, Ongaro F. Off-label use of hormones as an antiaging strategy: a review. Clin Interv Aging. 2014 Jul 23;9:1175-86. 
• Waghmare PS, Kaushik D, Oz E, Proestos C, Oz F, Kumar M. Unraveling the hormonal approaches for the treatment of rheumatoid arthritis and its complementary interventions. Inflammopharmacology. 2025 Feb;33(2):443-460. 
• Avila M, Bansal A, Culberson J, Peiris AN. The Role of Sex Hormones in Multiple Sclerosis. Eur Neurol. 2018;80(1-2):93-99. 
• Schwartz E, Morelli V, Holtorf K. Hormone replacement therapy in the geriatric patient: current state of the evidence and questions for the future–estrogen, progesterone, testosterone, and thyroid hormone augmentation in geriatric clinical practice: part 2. Clin Geriatr Med. 2011 Nov;27(4):561-75. doi: 10.1016/j.cger.2011.07.004. PMID: 22062441.
• Riepl M. Compounding to Prevent and Treat Dysbiosis of the Human Vaginal Microbiome. Int J Pharm Compd. 2018 Nov-Dec;22(6):456-465.
• Loflin BJ, Westmoreland K, Williams NT. Vulvodynia: A Review of the Literature. J Pharm Technol. 2019 Feb;35(1):11-24. 
• Gava G, Orsili I, Alvisi S, Mancini I, Seracchioli R, Meriggiola MC. Cognition, Mood and Sleep in Menopausal Transition: The Role of Menopause Hormone Therapy. Medicina (Kaunas). 2019 Oct 1;55(10):668. 
• Ruiz AD, Daniels KR, Barner JC, Carson JJ, Frei CR. Effectiveness of compounded bioidentical hormone replacement therapy: an observational cohort study. BMC Womens Health. 2011 Jun 8;11:27. 
• Gandhi J, Chen A, Dagur G, Suh Y, Smith N, Cali B, Khan SA. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol. 2016 Dec;215(6):704-711. 
• Faubion SS, Sood R, Kapoor E. Genitourinary Syndrome of Menopause: Management Strategies for the Clinician. Mayo Clin Proc. 2017 Dec;92(12):1842-1849.
• Ali ES, Mangold C, Peiris AN. Estriol: emerging clinical benefits. Menopause. 2017 Sep;24(9):1081-1085.  

Access package inserts for Estriol